<DOC>
	<DOCNO>NCT01359618</DOCNO>
	<brief_summary>This two part study . Part A determine maximum tolerate dose TC-5214 administer healthy male subject single ascend oral dos . This part study define high dose TC-5214 administer Part B . Part B study investigate effect TC-5214 electrical activity heart follow single oral administration . The study carry healthy male subject four period crossover study TC-5214 compare placebo oral moxifloxacin positive control . The safety , tolerability pharmacokinetics TC-5214 also evaluate .</brief_summary>
	<brief_title>Determining Highest Dose Administration TC-5214 Evaluating Effect Electrical Activity Heart</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male 18 50 year old inclusive suitable vein cannulation repeat venipuncture Have body mass index ( BMI ) 19 30 kg/m2 inclusive weigh least 50 kg Male subject willing use double barrier method contraception ( condom spermicide ) first dose investigational product 3 month last dose investigational product Be able understand comply requirement study judged investigator History clinically significant medical , neurologic psychiatric disease disorder , opinion Investigator Sponsor may either put subject risk participation study , influence result subject 's ability participate study History presence gastrointestinal ( include irritable bowel disease ) , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion study drug . Subjects history surgery gastrointestinal tract ( include appendectomy cholecystectomy ) also exclude History seizure activity , include febrile seizure Prolonged QTcF &gt; 450 m shorten QTcF &lt; 340 m , family history Long QT Syndrome Use concomitant medication prolong QT/QTc interval</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>healthy</keyword>
	<keyword>major depressive disorder</keyword>
	<keyword>thorough QT</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>elimination</keyword>
	<keyword>heart electrical signal</keyword>
</DOC>